Development of a multimodal predictive model using PET/CT radiomics and clinical data for preoperative assessment of lymphovascular invasion in gastric cancer
- PMID: 40821083
- PMCID: PMC12351560
- DOI: 10.62347/PBNU9406
Development of a multimodal predictive model using PET/CT radiomics and clinical data for preoperative assessment of lymphovascular invasion in gastric cancer
Abstract
Objectives: To develop and validate a multimodal predictive model combining positron emission tomography/computed tomography (PET/CT) radiomic features with clinical data for the preoperative assessment of lymphovascular invasion (LVI) in patients with gastric cancer (GC).
Methods: Between December 2017 and December 2022, 325 GC patients with pathologically confirmed LVI status were retrospectively enrolled. PET/CT scans were performed according to standard protocols, and 1,057 radiomic features were extracted from both imaging modalities following appropriate preprocessing. LASSO regression was used to select informative features for separate CT, PET, and combined PET/CT models. Key clinical variables - including age, maximum standardized uptake value, total lesion glycolysis, lymph node metastasis, and tumor grade - were integrated using multivariate logistic regression to construct a comprehensive predictive model. Model performance was assessed using ROC curve analysis. Diagnostic metrics - including AUC, sensitivity, specificity, accuracy, and Net Reclassification Improvement (NRI) - were calculated for each model.
Results: The CT, PET, and combined PET/CT models achieved AUCs of 0.823, 0.761, and 0.861, respectively. The final multimodal model integrating PET/CT radiomics with clinical data demonstrated superior performance, with an AUC of 0.904, specificity of 91.91% and sensitivity of 74.07%. Independent predictors of LVI included age, SUVmax, TLG, and lymph node metastasis. NRI analysis showed a 10.35% improvement in risk classification compared to the PET/CT radiomic model alone.
Conclusions: The multimodal predictive model demonstrated excellent diagnostic accuracy for preoperative assessment of LVI in GC patients and may support individualized treatment planning and risk stratification. Prospective multicenter studies are needed to further validate its clinical utility.
Keywords: Gastric cancer; lymphovascular invasion; multimodal model; positron emission tomography/computed tomography; radiomics.
AJTR Copyright © 2025.
Conflict of interest statement
None.
Figures



Similar articles
-
The correlation between preoperative total lesion glycolysis and lymphovascular invasion based on 18F-FDG PET/CT and its predictive value in primary gastric cancer: a cross-sectional study.Quant Imaging Med Surg. 2025 Sep 1;15(9):7738-7748. doi: 10.21037/qims-2025-644. Epub 2025 Aug 13. Quant Imaging Med Surg. 2025. PMID: 40893561 Free PMC article.
-
Quantification of Intratumoral Heterogeneity Based on Habitat Analysis for Preoperative Assessment of Lymphovascular Invasion in Colorectal Cancer.Acad Radiol. 2025 Aug;32(8):4532-4543. doi: 10.1016/j.acra.2025.03.014. Epub 2025 Apr 1. Acad Radiol. 2025. PMID: 40175205
-
PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer.Cochrane Database Syst Rev. 2014 Nov 13;2014(11):CD009519. doi: 10.1002/14651858.CD009519.pub2. Cochrane Database Syst Rev. 2014. PMID: 25393718 Free PMC article.
-
Multimodal Positron Emission Tomography/Computed Tomography Radiomics Combined with a Clinical Model for Preoperative Prediction of Invasive Pulmonary Adenocarcinoma in Ground-Glass Nodules.Acad Radiol. 2025 Aug 25:S1076-6332(25)00736-6. doi: 10.1016/j.acra.2025.07.067. Online ahead of print. Acad Radiol. 2025. PMID: 40858464
-
The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350. Health Technol Assess. 2011. PMID: 21958472 Free PMC article.
References
-
- Li J, Wang L, Hu W, Wu J, Chen H, Wang L, Lv B, Zhang X, Dai Y, Huang Z, Cai Z, Ding X, Ye L, Ding J, Xiang L, Ye B, Chen S, Si J. Effect of premedication with pronase before upper gastrointestinal endoscopy: a multicenter prospective randomized controlled study. J Clin Gastroenterol. 2024;58:53–56. - PubMed
-
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–263. - PubMed
-
- Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, Bhadkamkar NA, Deighton DC, Janjigian Y, Karippot A, Khan U, King DA, Klute K, Lacy J, Lee JJ, Mehta R, Mukherjee S, Nagarajan A, Park H, Saeed A, Semrad TJ, Shitara K, Smyth E, Uboha NV, Vincelli M, Wainberg Z, Rajdev L. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J. Clin. Oncol. 2023;41:1470–1491. - PubMed
-
- Takano K, Ashikari K, Tamura S, Misawa N, Takatsu T, Yoshihara T, Nonaka T, Arimoto J, Sakamoto A, Chiba H, Fujii S, Nakajima A, Higurashi T. Clinicopathological features of endoscopically treated early gastric cancer with lymphovascular infiltration. J Cancer Res Clin Oncol. 2023;149:5781–5790. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous